{"organizations": [], "uuid": "c9864615cb1eb3d2fe7cd188c488e8f4e02fee66", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180329.html", "section_title": "Archive News &amp; Video for Thursday, 29 Mar 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-sanofi-ema-to-review-sotagliflozin/brief-sanofi-ema-to-review-sotagliflozin-as-potential-treatment-for-type-1-diabetes-idUSASC09U4W", "country": "US", "domain_rank": 408, "title": "Sanofi: EMA to review sotagliflozin as potential treatment for type 1 diabetes", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.449, "site_type": "news", "published": "2018-03-29T13:36:00.000+03:00", "replies_count": 0, "uuid": "c9864615cb1eb3d2fe7cd188c488e8f4e02fee66"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-sanofi-ema-to-review-sotagliflozin/brief-sanofi-ema-to-review-sotagliflozin-as-potential-treatment-for-type-1-diabetes-idUSASC09U4W", "ord_in_thread": 0, "title": "Sanofi: EMA to review sotagliflozin as potential treatment for type 1 diabetes", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "sanofi", "sentiment": "negative"}, {"name": "european medicines agency", "sentiment": "negative"}, {"name": "lexicon pharmaceuticals, inc.", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "March 29 (Reuters) - Sanofi:\n* The European Medicines Agency (EMA) has accepted for review Sanofiâ€™s regulatory submission for sotagliflozin\n* If approved, the oral treatment would be used as an addition to insulin therapy to improve blood sugar control in adults with type 1 diabetes mellitus\n* Developed in partnership with Lexicon Pharmaceuticals, Inc., sotagliflozin is an investigational dual inhibitor of SGLT-1 and SGLT-2, proteins that influence how the intestines and kidneys process blood sugar (glucose)\n ", "external_links": ["https://twitter.com/reuters", "https://www.youtube.com/user/ReutersVideo", "https://www.linkedin.com/company/10256858/", "https://www.facebook.com/Reuters", "https://www.thomsonreuters.com/en/privacy-statement.html", "http://thomsonreuters.com/en/about-us/trust-principles.html", "https://instagram.com/reuters/"], "published": "2018-03-29T13:36:00.000+03:00", "crawled": "2018-03-30T12:47:02.007+03:00", "highlightTitle": ""}